In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss ...

If you are chasing peak performance or looking to build a powerful lower body, there’s one muscle group you’re probably not training: the adductors. Commonly re ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Common adverse events with bimagrumab-containing groups included muscle spasms (ranging from 46.4% with 10 mg to 63.6% with the high-dose combination), diarrhea, and acne, while semaglutide was ...

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

First FDA-Approved Therapy for Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC): Zusduri (mitomycin) is the first and only FDA-approved intravesical treatment ...

The FDA approved intravesical mitomycin (Zusduri, formerly UGN-102) in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer (NMIBC). The approval was supported by the ...

Discover what the mind-muscle connection really is, why it matters for building muscle and strength, and how to use it for ...

Discover how pelvic floor muscles coordinate with your diaphragm for optimal breathing and why dysfunction causes fatigue and ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones.